ストックスクリーナーアプリを入手
150.52
3.23%
-5.03
アフターアワーズ：
150.52
Charles River Laboratories International Inc (CRL) 最新ニュース
Charles River Labs stock hits 52-week low at $150.19 By Investing.com - Investing.com Australia
Baird Adjusts Charles River Laboratories International Price Target to $155 From $173, Maintains Neutral Rating - MarketScreener
Charles River Labs stock hits 52-week low at $150.19 - Investing.com
Mawer Investment Management Ltd. Buys 5,769 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - TradingView
Genetic Toxicology Testing Market To Witness Huge Gains Over - openPR
Biopharma Layoffs Roundup - Contract Pharma
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform - BioSpace
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MSN
Charles River, Valo Health Identify First Lupus Treatment Candidate Using Logica AI Platform - Marketscreener.com
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica - Business Wire
Why Charles River Laboratories International, Inc. (CRL) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Goldman Sachs Downgrades Charles River Laboratories International (CRL) - MSN
Demystifying Charles River: Insights From 10 Analyst Reviews - Benzinga
Icon stock, Charles River stock downgraded at Goldman (CRL) - Seeking Alpha
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga India
Goldman Sachs cuts Charles River Labs stock rating, target to $170 - Investing.com India
Goldman Sachs cuts Charles River Labs stock rating, target to $170 By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Charles River Laboratories International to Neutral From Buy, Adjusts Price Target to $170 From $190 - Marketscreener.com
Jefferies maintains Charles River Labs stock hold, price target at $169 - Investing.com Canada
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Interesting CRL Put And Call Options For November 21st - Nasdaq
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo Finance
Earnings call transcript: Charles River Labs beats Q4 2024 forecasts By Investing.com - Investing.com UK
Should You Investigate Charles River Laboratories International, Inc. (NYSE:CRL) At US$171? - Simply Wall St
Charles River Laboratories to Present at Barclays Global Healthcare Conference - BioSpace
Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - GlobeNewswire Inc.
Charles River Labs Management Reveals Strategic Roadmap at Major Healthcare Conference - Stock Titan
Mutual of America Capital Management LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Smartleaf Asset Management LLC Increases Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Fairjourney Biologics acquires Charles River Laboratories South San Francisco facility - MSN
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN
Charles River, LabCorp upgraded, Quest downgraded at Citi on valuation - MSN
Charles River announces agreement with Singapore General Hospital - SelectScience
Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Citigroup - Defense World
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Charles River Laboratories Shares Rise After Citigroup Upgrade -March 04, 2025 at 02:53 pm EST - Marketscreener.com
Citi raises Charles River stock rating, lifts target to $175 - Investing.com
Citi raises Charles River stock rating, lifts target to $175 By Investing.com - Investing.com South Africa
Citigroup Upgrades Charles River Laboratories International to Neutral From Sell, Adjusts Price Target to $175 From $155 - Marketscreener.com
FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility - Joplin Globe
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of “Reduce” from Brokerages - Defense World
Charles River Laboratories International (NYSE:CRL) Rating Increased to Neutral at Redburn Atlantic - Defense World
Pricing woes and policy shifts shape Charles River’s 2025 outlook - BioProcess Insider
High-Throughput Screening Technology Analysis and Global - GlobeNewswire
Redburn raises Charles River Labs stock to neutral, ups target to $188 - Investing.com Australia
Redburn Atlantic Upgrades Charles River Laboratories International to Neutral From Sell, Adjusts PT to $188 From $171 - Marketscreener.com
1.12%
1.76%
大文字化:
|
ボリューム (24 時間):